Company News
Nectar Lifesciences Major Restructuring with ₹12.5B Asset Sales
Nectar Lifesciences completed slump sale of pharmaceutical businesses for ₹12.54B to Ceph Lifesciences, resulting in ₹1.63B exceptional gain but FY26 net loss of ₹2.93B.
Company executed ₹810M share b
